HiveProspectStranded Biotech Asset IntelligenceResearch intelligence
Research workspace tools

Find → Understand → Decide

Fludarabine Phosphate

Discovery priority: LOW · POSSIBLE / INVESTIGATE

Discovery priority ≠ investment recommendation. These are observation labels, not verified canonical products. Buyer qualification: UNKNOWN.

Why investigate?

Why stranded (event context): inadequate public evidence

Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established

Company/trial failed before biology? UNKNOWN

Biology implicated: UNCLEAR · Failure context: UNKNOWN

MODEL INFERENCE · LOW confidence. Explicit asset-linked program event or documented experimental trial arm, stop scope, dated recency and biological cautions; no publication count or buyer-gate input.

Current control: UNKNOWN · Restart: UNKNOWN · Development reuse: UNKNOWN

Next diligence: Confirm present program status and exact product identity, then trace scoped rights/data/CMC and review arm-level human outcomes.

Existing buyer gates

Human Signal: UNKNOWN

Cheap Truth: UNKNOWN

Clean Rights: UNKNOWN

Market Pull: UNKNOWN

No event or publication count supplies missing gate evidence. Existing reviewed opportunities remain in their original records.

Evidence timeline

2026-03-30 · trial:NCT02333162

Registry update date, not proven program-stop date

SOURCE TEXT · Exact source

Enrollment on hold pending amendment

Trial reason is not attributed to every intervention; comparator/combination context needs review.

Interpretation: inadequate public evidence · AUTO_INFERRED · MEDIUM

Provenance and retrieval scope
{
  "hash": "d48f3d5225b2eaa8c72cc73700f79f2da8a28af0cb59562df5cb29ac7a29d1ee",
  "metadata": {
    "complete": false,
    "content_hash": "38a1f6b0acab83e32f1bc4be6780a423f51adefad10b1134fa1db1296649450e",
    "failed": false,
    "last_checked": 1790026984.0751398,
    "last_success": 1790026984.0751398,
    "live_verified": true,
    "scope": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
  },
  "path": "protocolSection.armsInterventionsModule.interventions",
  "raw_hash": "38a1f6b0acab83e32f1bc4be6780a423f51adefad10b1134fa1db1296649450e",
  "raw_path": "research/obz7_sources/38a1f6b0acab83e32f1bc4be6780a423f51adefad10b1134fa1db1296649450e.json",
  "request_params": {
    "countTotal": "true",
    "format": "json",
    "pageSize": 100,
    "query.term": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
    "sort": "LastUpdatePostDate:desc"
  },
  "request_url": "https://clinicaltrials.gov/api/v2/studies",
  "type": "clinicaltrials",
  "url": "https://clinicaltrials.gov/study/NCT02333162"
}

2026-07-14 · trial:NCT05400122

Registry update date, not proven program-stop date

SOURCE TEXT · Exact source

Drugs unavailable

Trial reason is not attributed to every intervention; comparator/combination context needs review.

Interpretation: inadequate public evidence · AUTO_INFERRED · MEDIUM

Provenance and retrieval scope
{
  "hash": "ef64916f4225cb5aa8cdee060189b53535b538d1c8c71fa1471f280b66e19690",
  "metadata": {
    "complete": false,
    "content_hash": "2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed",
    "failed": false,
    "last_checked": 1790026985.182528,
    "last_success": 1790026985.182528,
    "live_verified": true,
    "scope": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
  },
  "path": "protocolSection.armsInterventionsModule.interventions",
  "raw_hash": "2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed",
  "raw_path": "research/obz7_sources/2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed.json",
  "request_params": {
    "countTotal": "true",
    "format": "json",
    "pageSize": 100,
    "query.term": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
    "sort": "LastUpdatePostDate:desc"
  },
  "request_url": "https://clinicaltrials.gov/api/v2/studies",
  "type": "clinicaltrials",
  "url": "https://clinicaltrials.gov/study/NCT05400122"
}

2026-07-31 · trial:NCT05703854

Registry update date, not proven program-stop date

SOURCE TEXT · Exact source

PI Request

Trial reason is not attributed to every intervention; comparator/combination context needs review.

Interpretation: inadequate public evidence · AUTO_INFERRED · MEDIUM

Provenance and retrieval scope
{
  "hash": "2dc8d06aa1e8b3bd8078142152573bdcb6a669ee082b1f0425046f56ce352c00",
  "metadata": {
    "complete": false,
    "content_hash": "2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed",
    "failed": false,
    "last_checked": 1790026985.182528,
    "last_success": 1790026985.182528,
    "live_verified": true,
    "scope": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
  },
  "path": "protocolSection.armsInterventionsModule.interventions",
  "raw_hash": "2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed",
  "raw_path": "research/obz7_sources/2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed.json",
  "request_params": {
    "countTotal": "true",
    "format": "json",
    "pageSize": 100,
    "query.term": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
    "sort": "LastUpdatePostDate:desc"
  },
  "request_url": "https://clinicaltrials.gov/api/v2/studies",
  "type": "clinicaltrials",
  "url": "https://clinicaltrials.gov/study/NCT05703854"
}

2026-08-05 · trial:NCT04539366

Registry update date, not proven program-stop date

SOURCE TEXT · Exact source

Other - review of safety data

Trial reason is not attributed to every intervention; comparator/combination context needs review.

Interpretation: inadequate public evidence · AUTO_INFERRED · MEDIUM

Provenance and retrieval scope
{
  "hash": "4afa7956f465b9fc314229f75de162e57169f1ce0ea7869425f859db858a8795",
  "metadata": {
    "complete": false,
    "content_hash": "2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed",
    "failed": false,
    "last_checked": 1790026985.182528,
    "last_success": 1790026985.182528,
    "live_verified": true,
    "scope": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
  },
  "path": "protocolSection.armsInterventionsModule.interventions",
  "raw_hash": "2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed",
  "raw_path": "research/obz7_sources/2ca1679dad0f3f17150af6bd4f23c7bb11e653d2dd78fd7c22183dc1902caeed.json",
  "request_params": {
    "countTotal": "true",
    "format": "json",
    "pageSize": 100,
    "query.term": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
    "sort": "LastUpdatePostDate:desc"
  },
  "request_url": "https://clinicaltrials.gov/api/v2/studies",
  "type": "clinicaltrials",
  "url": "https://clinicaltrials.gov/study/NCT04539366"
}

Freshness is claim-specific

Fetching an old filing today does not establish current ownership or program status.

pipeline · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN

sec · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN

rights · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN

contact · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN

patent_assignment · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN

clinicaltrials · STALE · AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:04.075140+00:00

clinicaltrials · STALE · AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:05.182528+00:00

clinicaltrials · STALE · AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:05.182528+00:00

clinicaltrials · STALE · AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2015-01-01,2026-09-21] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:05.182528+00:00

Registry observations (4)

NCT02333162 · SUSPENDED · PHASE1 · Previously Treated Myelodysplastic Syndrome; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Hematologic Malignancy · Trial sponsor University of Chicago

Reported aliases: 2-F-ara-AMP; Beneflur; SH T 586. Identity, treatment role and exposure require review.

NCT04539366 · SUSPENDED · PHASE1 · Recurrent Childhood Neuroblastoma; Recurrent Childhood Osteosarcoma; Recurrent Neuroblastoma; Recurrent Osteosarcoma; Refractory Childhood Neuroblastoma; Refractory Childhood Osteosarcoma; Refractory Neuroblastoma; Refractory Osteosarcoma · Trial sponsor National Cancer Institute (NCI)

Reported aliases: 2-F-ara-AMP; 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-; Beneflur; Fludara; SH T 586. Identity, treatment role and exposure require review.

NCT05703854 · SUSPENDED · PHASE1, PHASE2 · Advanced Renal Cell Carcinoma; Advanced Mesothelioma; Advanced Osteosarcoma · Trial sponsor M.D. Anderson Cancer Center

Reported aliases: Fludarabine; Fludara®. Identity, treatment role and exposure require review.

NCT05400122 · SUSPENDED · PHASE1 · Colorectal Cancer; Hematologic Malignancy; Rectum Cancer; Acute Myeloid Leukemia; Myelodysplastic Syndromes; Acute Lymphoblastic Leukemia; Chronic Myeloid Leukemia; Chronic Lymphocytic Leukemia; Hodgkin Lymphoma; Non Hodgkin Lymphoma; Myeloproliferative Syndrome; Plasma Cell Myeloma; Gastric Cancer; Esophageal Cancer; Esophagus Cancer; Gastric Cancer, Metastatic; Unresectable Esophageal Cancer; Metastatic Esophageal Cancer · Trial sponsor David Wald

Reported aliases: Fludara. Identity, treatment role and exposure require review.

Back to discovery